retatrutide experience Retatrutide—A Game Changer in Obesity Pharmacotherapy Understanding the Retatrutide starting dose

especially as scanning hardware improves (things like the ArchSpine AirBox)

J Neurol Neurosurg Psychiatry 86(2):168173

The backstory: CVS Caremark, the nations largest pharmacy benefit manager, stopped covering Zepbound on July 1, 2025, after reaching a deal with Novo Nordisk, the maker of rival GLP-1 drug Wegovy

Sarcopenia is common among older adults with obesity and NASH patients with cirrhosis leading to increased risk for lower bone density, decreased strength and mortality

In cellular models, SLU-PP-332 augments oxygen consumption rate and induces Ddit4 and other metabolic stress-response genes consistent with increased mitochondrial flux

Modulates Blood Lipids : GLP-1 can lead to favorable changes in blood lipid profiles, potentially lowering LDL ("bad") cholesterol and triglycerides while increasing HDL ("good") cholesterol